Potency and safety analysis of hemp-derived delta-9 products: The hemp vs. cannabis demarcation problem

Legal status
Legal status
  • [1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.233.198 Edit this at Wikidata
Chemical and physical data
Molar mass354.494 g·mol−1
3D model (JSmol)
  • C4COCCN4CCn(c3ccccc13)cc1C(=O)C2C(C)(C)C2(C)C
  • InChI=1S/C22H30N2O2/c1-21(2)20(22(21,3)4)19(25)17-15-24(18-8-6-5-7-16(17)18)10-9-23-11-13-26-14-12-23/h5-8,15,20H,9-14H2,1-4H3 checkY
 ☒NcheckY (what is this?)  (verify)

A-796,260 is a drug developed by Abbott Laboratories that acts as a potent and selective cannabinoid CB2 receptor agonist. Replacing the aromatic 3-benzoyl or 3-naphthoyl group found in most indole derived cannabinoids with the 3-tetramethylcyclopropylmethanone group, imparts significant selectivity for CB2, and A-796,260 was found to be a highly selective CB2 agonist with little affinity for CB1, having a CB2 Ki of 4.6 nM vs 945 nM at CB1.[1] It has potent analgesic and anti-inflammatory actions in animal models, being especially effective in models of neuropathic pain, but without producing cannabis-like behavioral effects.[2]

Legal Status

As of October 2015 A-796,260 is a controlled substance in China.[3]

See also


  1. ^ Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, et al. (January 2010). "Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity". Journal of Medicinal Chemistry. 53 (1): 295–315. doi:10.1021/jm901214q. PMID 19921781.
  2. ^ Yao BB, Hsieh GC, Frost JM, Fan Y, Garrison TR, Daza AV, et al. (January 2008). "In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models". British Journal of Pharmacology. 153 (2): 390–401. doi:10.1038/sj.bjp.0707568. PMC 2219533. PMID 17994110.
  3. ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.